{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:04:15Z","timestamp":1792184655242,"version":"4.4.0"},"reference-count":22,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Takeda Pharmaceuticals International Inc. and H. Lundbeck A\/S"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Depress Anxiety"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1002\/da.22702","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T19:32:45Z","timestamp":1511379165000},"page":"1164-1172","source":"Crossref","is-referenced-by-count":27,"title":["Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder"],"prefix":"10.1155","volume":"34","author":[{"given":"Michael R.","family":"Liebowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Careri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra","family":"Blatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9732-1059","authenticated-orcid":false,"given":"Ann","family":"Draine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Hanover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"key":"10.1002\/da.22702-BIB0001|da22702-cit-0001","first-page":"589","article-title":"A double blind, randomized, placebo controlled, active reference study of Lu AA21004 in individuals with major depressive disorder","volume":"15","author":"Alvarez","year":"2012","journal-title":"Int J Neuropharmacology"},{"key":"10.1002\/da.22702-BIB0002|da22702-cit-0002","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jad.2016.07.015","article-title":"A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms","volume":"206","author":"Baldwin","year":"2016","journal-title":"J of Affective Disorders"},{"issue":"3","key":"10.1002\/da.22702-BIB0003|da22702-cit-0003","first-page":"242","article-title":"The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies","volume":"30","author":"Baldwin","year":"2016","journal-title":"J of Pharmacology"},{"key":"10.1002\/da.22702-BIB0004|da22702-cit-0004","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archpsyc.64.8.903","article-title":"Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life","volume":"64","author":"Beesdo","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.22702-BIB0005|da22702-cit-0005","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.euroneuro.2012.07.012","article-title":"Vortioxetine (LU AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial","volume":"22","author":"Bidzan","year":"2012","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/da.22702-BIB0006|da22702-cit-0006","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/da.10096","article-title":"Pharmacological treatment of social anxiety disorder: A meta-analysis","volume":"18","author":"Blanco","year":"2003","journal-title":"Depression and Anxiety"},{"key":"10.1002\/da.22702-BIB0007|da22702-cit-0007","first-page":"218","article-title":"Assessment Manual for Psychiatry - Revised","volume":"76-338","author":"Guy","year":"1976","journal-title":"DHEW Publ No Adm"},{"key":"10.1002\/da.22702-BIB0008|da22702-cit-0008","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"key":"10.1002\/da.22702-BIB0009|da22702-cit-0009","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/jsm.12980","article-title":"Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction","volume":"12","author":"Jacobsen","year":"2015","journal-title":"J Sex Med"},{"key":"10.1002\/da.22702-BIB0010|da22702-cit-0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000414022","article-title":"Social Phobia","volume":"22","author":"Liebowitz","year":"1987","journal-title":"Mod Probl Pharmacopsychiatry"},{"key":"10.1002\/da.22702-BIB0011|da22702-cit-0011","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4088\/JCP.v66n0213","article-title":"Venlafaxine extended release in generalized social anxiety disorder","volume":"66","author":"Liebowitz","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22702-BIB0012|da22702-cit-0012","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hup.2371","article-title":"A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 25 and 10mg in acute treatment of adults with generalized anxiety disorder","volume":"29","author":"Mahableshwarkar","year":"2014a","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"10.1002\/da.22702-BIB0013|da22702-cit-0013","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ijcp.12328","article-title":"A randomized, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalized anxiety disorder","volume":"68","author":"Mahableshwarkar","year":"2014b","journal-title":"Int J Clin Pract"},{"key":"10.1002\/da.22702-BIB0014|da22702-cit-0014","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"10.1002\/da.22702-BIB0015|da22702-cit-0015","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4088\/JCP.v66n1009","article-title":"A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. (2005)","volume":"66","author":"Montgomery","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22702-BIB0016|da22702-cit-0016","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.euroneuro.2012.07.011","article-title":"Vortioxetine (LU AA21004) 5 mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States","volume":"22","author":"Rothschild","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1002\/da.22702-BIB0017|da22702-cit-0017","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/da.10112","article-title":"Citalopram treatment of social anxiety disorder comorbid with major depression","volume":"17","author":"Schneier","year":"2003","journal-title":"Depression and Anxiety"},{"key":"10.1002\/da.22702-BIB0018|da22702-cit-0018","volume-title":"The Anxiety Disease","author":"Sheehan","year":"1983"},{"key":"10.1002\/da.22702-BIB0019|da22702-cit-0019","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1001\/archpsyc.58.3.251","article-title":"Social anxiety disorder and the risk of depression","volume":"58","author":"Stein","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.22702-BIB0020|da22702-cit-0020","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.280.8.708","article-title":"Paroxetine treatment of generalized social phobia (social anxiety disorder); A randomized controlled trial","volume":"280","author":"Stein","year":"1998","journal-title":"JAMA"},{"key":"10.1002\/da.22702-BIB0021|da22702-cit-0021","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1176\/appi.ajp.158.2.275","article-title":"Sertraline treatment of generalized social phobia: A 20-week, double-blind, placebo-controlled study","volume":"158","author":"Amerigen","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22702-BIB0022|da22702-cit-0022","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02244762","article-title":"Psychopharmacological treatment of social phobia: A double-blind, placebo-controlled study with fluvoxamine","volume":"115","author":"Vliet","year":"1994","journal-title":"Psychopharmacology"}],"container-title":["Depression and Anxiety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fda.22702","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/da.22702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:04:56Z","timestamp":1671541496000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/da.22702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,22]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"URL":"https:\/\/doi.org\/10.1002\/da.22702","archive":["Portico"],"relation":{},"ISSN":["1091-4269"],"issn-type":[{"value":"1091-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11,22]]}}}